Shire Announces FDA Approval Of Once-Daily INTUNIV™ Extended Release Tablets For The Treatment Of ADHD In Children And Adolescents Aged 6 To 17
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV™ (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years.
See more here:
Related posts:
- Abbott Statement On ARBITER 6 – HALTS Results And Abbott’s Niaspan (Niacin Extended-Release)
- Mylan’s Matrix Receives Tentative FDA Approval Under PEPFAR For Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate Tablets
- Teva Receives Final Approval For Generic Prevacid(R) Delayed-Release Capsules
- Novartis Receives Approval In The European Union For Onbrez® Breezhaler®, A New Once-daily Bronchodilator For Patients With COPD
- Students With ADHD Benefit From Meditation